B-cell Lymphoma: Clinical Trials

73 trials for B-cell Lymphoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

28 completed, 16 recruiting, 10 terminated, 10 unknown. 73 Phase 1, 21 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 173Completed 28, Recruiting 16, Terminated 10, Unknown 10, Active not recruiting 4, Withdrawn 4, Enrolling by invitation 1
Phase 221Completed 7, Recruiting 7, Terminated 3, Unknown 2, Withdrawn 2

Follow B-cell Lymphoma: new trials by email Literature Review of B-cell Lymphoma trials Research Report on B-cell Lymphoma

Trials (filtered) newest first · largest first

All 73 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
NX-5948, venetoclax, rituximab - B-cell Lymphoma, Chronic Lymphocytic Leukemia
Phase 1 / Phase 2RecruitingNurix Therapeutics, Inc.1502026-09-302026-11-03
Phase I Study of FXS0683 in the Treatment of Blood Tumors
FXS0683 - B-Cell Lymphoma, Acute Myeloid Leukemia
Phase 1RecruitingShanghai Fosun Pharmaceutical Industrial Development Co. Ltd.2282026-06-022026-10-14
In Vivo CD19/CD20 CAR T-Cell Therapy for Relapsed/Refractory B-Cell Lymphoma
SL1617 Injection - B-cell Lymphoma
Phase 1RecruitingChinese PLA General Hospital182026-06-012026-08-20
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
LY4152199 - IV - Lymphoma, Non-Hodgkin, B-cell Lymphoma
Phase 1RecruitingEli Lilly and Company2152026-05-282026-11-04
Safety and Efficacy Study of BAFF-R CAR-T Cells in Adult Subjects With CD19-Negative Relapsed or Refractory B-Cell Lymphoma
BAFF-R CAR-T cells - B-cell Lymphoma
Phase 1RecruitingJiangsu Topcel-KH Pharmaceutical Co., Ltd.302026-01-012026-02-27
Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies
CAR-T - Multiple Myeloma, B-cell Lymphoma
Phase 1RecruitingThe Third Affiliated Hospital of Southern Medical University602025-01-152025-01-06
A Study of XS-04 in Patients With Relapsed or Refractory Hematologic Malignancies
XS-04 tablet - B-cell Lymphoma, Acute Myeloid Leukemia
Phase 1RecruitingShanghai Fosun Pharmaceutical Industrial Development Co. Ltd.1682025-01-142026-09-25
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
CLIC-2201 - B-Cell Leukemia, Non-Hodgkin's Lymphoma
Phase 1RecruitingBritish Columbia Cancer Agency242025-01-022026-10-14
A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Tacabrutideg, Sonrotoclax, Zanubrutinib - B-cell Malignancy, Relapsed Cancer
Phase 1 / Phase 2RecruitingBeOne Medicines802024-11-272026-09-11
Clinical Study of Multi-targeted CAR-T Therapy in Patients With Relapsed/Refractory B-Cell Lymphoma
Triple-targeted CAR-T Therapy - B-cell Lymphoma
Phase 1WithdrawnShanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd2024-11-072026-05-06
CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas
CD19.20.22 CAR T cells, Fludarabine and Cyclophosphamide - B-Cell Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL)
Phase 1Enrolling by invitationUniversity of Maryland, Baltimore152024-10-282026-09-14
A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas
ASP2802, MA-20 - B-cell Lymphoma
Phase 1TerminatedAstellas Pharma Global Development, Inc.12024-09-062025-10-28
CAR20(NAP)-T Therapy for B Cell Lymphoma (CARMA-01 Study)
CAR20(NAP)-T, Cyclophosphamide, Fludarabine - B-cell Lymphoma
Phase 1 / Phase 2RecruitingUppsala University182024-05-012026-11-10
A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas
Tazemetostat Pill - Follicular Lymphoma, B-Cell Lymphoma
Phase 1Active not recruitingWeill Medical College of Cornell University152023-10-042026-06-17
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
IKS03 - B-cell Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma
Phase 1RecruitingIksuda Therapeutics Ltd.1402023-09-052026-11-03
A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies
Anti-CD19 Autologous CAR-T Cell Infusion - B-Cell Leukemia, B-Cell Lymphoma
Phase 1 / Phase 2Unknown920th Hospital of Joint Logistics Support Force of People's Liberation Army of China602023-07-012023-07-11
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
CTX112 - B-cell Lymphoma, Non-Hodgkin Lymphoma
Phase 1 / Phase 2RecruitingCRISPR Therapeutics AG1202023-03-102025-11-14
Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma
19(T2)28z1xx TRAC T cell - B-Cell Lymphoma, Large B-cell Lymphoma
Phase 1Active not recruitingMemorial Sloan Kettering Cancer Center302023-02-232026-04-22
Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies
Etoposide, Doxorubicin, Cyclophosphamide - B-cell Lymphoma, Burkitt Lymphoma
Phase 1Active not recruitingMedical College of Wisconsin112023-01-262026-10-14
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
Cyclophosphamide, Fludarabine, ACE1831 - B-cell Lymphoma, Non Hodgkin Lymphoma
Phase 1CompletedAcepodia Biotech, Inc.162023-01-212026-06-30

Showing 20 of 73. Sign in to see all of them.

Narrower conditions

Lymphoma, B-Cell (73)  ·  Lymphoma, Non-Hodgkin (21)  ·  Lymphoma, Mantle-Cell (16)  ·  Lymphoma (15)  ·  Lymphoma, Follicular (15)  ·  Burkitt Lymphoma (12)  ·  Lymphoma, B-Cell, Marginal Zone (12)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (11)  ·  Leukemia, B-Cell (10)  ·  Lymphoma, Large B-Cell, Diffuse (10)  ·  Recurrence (8)  ·  Waldenstrom Macroglobulinemia (8)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (6)  ·  Multiple Myeloma (5)  ·  Leukemia, Myeloid, Acute (4)

Broader conditions

Hemic and Lymphatic Diseases (73)  ·  Immune System Diseases (73)  ·  Immunoproliferative Disorders (73)  ·  Lymphatic Diseases (73)  ·  Lymphoproliferative Disorders (73)  ·  Neoplasms by Histologic Type (73)  ·  Neoplasms (70)  ·  Lymphoma (58)  ·  Lymphoma, Non-Hodgkin (52)  ·  Hematologic Diseases (30)  ·  Leukemia (24)  ·  Leukemia, Lymphoid (21)  ·  Pathologic Processes (20)  ·  Pathological Conditions, Signs and Symptoms (20)  ·  Disease Attributes (18)

Interventions

Rituximab (13)  ·  Cyclophosphamide (11)  ·  fludarabine (9)  ·  obinutuzumab (7)  ·  Etoposide (4)  ·  venetoclax (4)  ·  Gemcitabine (3)  ·  Interleukin-2 (3)  ·  Prednisone (3)  ·  glofitamab (3)  ·  ibrutinib (3)  ·  Acetaminophen (2)  ·  Bendamustine Hydrochloride (2)  ·  Cytarabine (2)  ·  Dexamethasone (2)

Sponsors

National Cancer Institute (NCI) (3)  ·  920th Hospital of Joint Logistics Support Force of People's Liberation Army of China (2)  ·  CRISPR Therapeutics AG (2)  ·  Eli Lilly and Company (2)  ·  Hoffmann-La Roche (2)  ·  M.D. Anderson Cancer Center (2)  ·  Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (2)  ·  TG Therapeutics, Inc. (2)  ·  The Lymphoma Academic Research Organisation (2)  ·  AbbVie (1)  ·  Acepodia Biotech, Inc. (1)  ·  Acrotech Biopharma Inc. (1)  ·  Agenus Inc. (1)  ·  Astellas Pharma Global Development, Inc. (1)  ·  Astellas Pharma Inc (1)

Countries

United States (38)  ·  China (24)  ·  Australia (11)  ·  France (8)  ·  Italy (8)  ·  Germany (6)  ·  Spain (6)  ·  Canada (5)  ·  Poland (5)  ·  United Kingdom (5)  ·  South Korea (4)  ·  Belgium (3)  ·  Sweden (3)  ·  Denmark (2)  ·  Hong Kong (2)

Top investigators

Abraham Leung, MD (1)  ·  Andrew Davies, Prof (1)  ·  Annie Weaver, PhD (1)  ·  Arturo Molina, MD (1)  ·  Baijun Fang, Prof. (1)  ·  Caitlin K Gribbin, M.D. (1)  ·  Carlos Ramos, MD (1)  ·  David Marin, MD (1)

Results publications

PMID 23045577, PMID 23295790, PMID 25381051, PMID 26193343, PMID 26966027, PMID 27482888, PMID 31011207, PMID 33676628, PMID 34398557, PMID 34464155, PMID 34687939, PMID 34780125, PMID 34889384, PMID 35383885, PMID 35432352, PMID 35488407, PMID 35595730, PMID 35605184, PMID 35798714, PMID 35900694, PMID 36059523, PMID 36477110, PMID 37192437, PMID 37407001, PMID 37486616, PMID 37624619, PMID 37774014, PMID 37883795, PMID 38376944, PMID 38502198, PMID 38598516, PMID 38861666, PMID 39033770, PMID 39415923, PMID 40000354, PMID 40610174, PMID 40749164, PMID 40845254, PMID 41055698, PMID 41144785, PMID 41544219, PMID 42069409, PMID 42085626, PMID 42248607, PMID 42496861, PMID 42786239, PMID 42789493

NIH funding

2017 (2), 2005 (1), 2015 (1), 2018 (1), 2025 (1), R01CA141303 (1)